E obtained Hter Tagesschl drowsiness Cidofovir Vistide Frequency and nocturia, has 12% of adults in Europe and North America. Negative impact on ATO The quality of life T in terms of health and impact on health Lebensqualit t may be more severe in some patients also reported OAB incontinence. Antimuscarinics are the first line of pharmacological treatment of overactive bladder, although the efficacy and reps Opportunity vary between agents and patients. Increasing doses of antimuscarinics k Nnte addicted To be effective, but it is not the g Ngigen clinical practice. Although a parallel study was made with a fixed dose of oxybutynin evidence of dose-response efficacy are available, have no fixed-dose studies with darifenacin and solifenacin. There is a increased Hte incidence of dry mouth with h Higher doses of antimuscarinic fixed dose studies. Antimuscarinic fesoterodine is developed to treat symptoms of overactive bladder, it is 4 or 8 mg tablets once t Possible. Fixed-dose Phase III studies demonstrated that fesoterodine 4 or 8 mg once t Possible significant symptoms of overactive bladder and Ma Measures of health-related Lebensqualit t improvement compared to placebo. Fesoterodine 4 and 8 mg also significantly improved the symptoms of overactive bladder, a symptom I st Pension and health Lebensqualit t in both flexible dose studies. The post hoc analysis shows that the symptoms of overactive bladder and patients studied, there is a label, flexible dose open label study with data stratified by topic reported The decision to escalate the dose of fesoterodine 4 to 8 mg at week 4, assesses the impact of flexible, optimized patient dose fesoterodine. PATIENTS AND METHODS STUDY DESIGN The design of this multicenter study is reported elsewhere. In short, included the study a 12-w Chige open-label, single arm, flexible study to investigate the effect of fesoterodine on symptoms of overactive bladder treatment and satisfaction, adult subjects with OAB who were with previous tolterodine or tolterodine therapy extended release dissatisfied. Symptoms of overactive bladder base were tested using a bladder diary 5 days w During a period of two weeks of testing. Subjects rated the sensation with urination or UUI episode in the newspaper about the five-point Urinary Sensation Scale-connected. All subjects were enrolled again U fesoterodine 4 mg once t Possible for 4 weeks, fesoterodine in the morning. At week 4, k Nnten participants either keep the dose fesoterodine 4 mg once t Possible or increased You increase the dose of 8 mg once t Was like for the last 8 weeks of the study, based on a conversation Ch between the subject and the interviewer about their subjective Power ON Tzung the effectiveness and possibility reps treatment. The study was conducted in accordance with the guidelines of good clinical practice and the Declaration of Helsinki. The protocol was approved by the Institutional Review Boards or their authorized independent Independent Ethics Committees and written informed consent all subjects before the start of the study. Topics such as mentioned above HNT, M Men and women aged 18 years with self-reported symptoms My OAB were eligible for 3 months before screening, with an average H FREQUENCY of urination eight or more micturitions per 24 hours and a period of three or more episodes of urgency per 24 h in a newspaper of the bubble 5 days at the beginning of the study. Respondents assessed their state of the bladder, causing at least moderate ome problems On the patient perception of bladder condition questionnaire initially Highest. Subjects had been treated with tolterodine or tolterodine E.